Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

The Human Research Ethics Committee (HREC) in Australia has granted clearance for Cullinan Therapeutics to commence an ...

InnoCare Pharma gets Chinese nod to begin clinical trial of BCL2 inhibitor ICP-248 for acute myeloid leukaemia: Beijing Friday, September 20, 2024, 18:00 Hrs [IST] InnoCare Pharma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

Finding oneself at an advanced stage of disease is devastating and may diminish one’s hope for the future. Participation in a ...

Top-line results were announced from a phase 3 trial evaluating nerandomilast for the treatment of idiopathic pulmonary fibrosis.

The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.

HighField Biopharmaceuticals’ new immuno-oncology drug molecule HF1K16 shows safe and signals efficacy in treating refractory metastatic cancers: Hanghou, China Wednesday, Septe ...

A: The majority of inquiries are related to regulatory issues, such as the drug review process, and are classified as follows: investigational new drugs (16%), new drugs (13%), generic drugs (17% ...

Topline data from FIBRONEER-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 vers ...

Boehringer Ingelheim will submit a new drug application for nerandomilast for the treatment ... Nerandomilast is an oral, ...